Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Free Cash Flow (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Free Cash Flow for 15 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow rose 167.68% year-over-year to $1.5 million, compared with a TTM value of -$8.0 million through Sep 2025, down 136.54%, and an annual FY2024 reading of $27.0 million, up 257.38% over the prior year.
  • Free Cash Flow was $1.5 million for Q3 2025 at Fennec Pharmaceuticals, up from -$3.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $37.3 million in Q1 2024 and bottomed at -$8.4 million in Q2 2024.
  • Average Free Cash Flow over 5 years is -$1.4 million, with a median of -$3.7 million recorded in 2025.
  • Peak annual rise in Free Cash Flow hit 768.94% in 2024, while the deepest fall reached 112.54% in 2024.
  • Year by year, Free Cash Flow stood at -$4.4 million in 2021, then plummeted by 53.68% to -$6.8 million in 2022, then increased by 28.55% to -$4.9 million in 2023, then skyrocketed by 69.67% to -$1.5 million in 2024, then soared by 201.29% to $1.5 million in 2025.
  • Business Quant data shows Free Cash Flow for FENC at $1.5 million in Q3 2025, -$3.7 million in Q2 2025, and -$4.3 million in Q1 2025.